Features

Emerging Pharma companies are an important partner to larger companies in drug development and as customers to CDMOs/CMOs. What has been the impact thus far on evolving US trade policy, including tariffs, and changes in healthcare policy and funding? DCAT Value Chain Insights takes an inside look.

President Donald Trump issued an Executive Order this week to lay out a plan to implement most-favored-nation drug pricing as a way to reduce differentials in drug pricing between the US and foreign countries as means to lower the cost of Rx drugs in the US. What’s the impact of pharma manufactuers?

President Donald Trump signed an Executive Order this week to facilitate drug manufacturing in the US, including calling for measures to streamline FDA and EPA review of domestic pharma manufacturing and enhance review of foreign drug-manufacturing facilities. What’s next?

Riding the strength of GLP-1 agonists and renewed interest in peptide-based development, several CDMOs are proceeding with large-scale investments in peptide development and manufacturing as other companies are joining the peptide space.

What stands out in the first quarter 2025 results and year-to-date activity of the large bio/pharmaceutical companies? Is it business as usual? What developments stand out, and what may be in store for the balance of 2025?

Orphan drugs have accounted for more than 50% of new drug approvals over the past five years and are projected to account for 20% of the global Rx drug market by 2030, but are market prospects slowing?

Expansions in biomanufacturing (biologic drug substances) continues to be an active area of investment by CDMOs/CMOs. Which companies are expanding? DCAT Value Chain Insights rounds up the latest developments.

Biotech industry groups, Biotechnology Innovation Organization (US) and EuropaBio (Europe), weigh in on evolving US trade policy and how to strengthen the life-sciences industry’s competitiveness.

The US Secretary of Commerce has initiated an investigation to determine the effects on US national security of imports of pharmaceuticals, including finished drug products, active pharmaceutical ingredients (APIs), and key starting materials, potentially paving the way for pharmaceutical industry-specific tariffs.

President Donald Trump has signed an Executive Order on drug pricing, which calls for eliminating the so-called “pill penalty” under the Medicare Prescription Drug Negotiation Program to equalize the post-approval time frame for drugs subject to negotiation for small-molecule drugs and biologics.